Olema Pharmaceuticals, Inc.
OLMA
$5.59
-$0.17-2.95%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -6.74% | 0.19% | -5.74% | -0.51% | -11.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.19% | 32.83% | 30.77% | 35.11% | 20.82% |
| Operating Income | -23.19% | -32.83% | -30.77% | -35.11% | -20.82% |
| Income Before Tax | -29.80% | -29.75% | -33.95% | -27.71% | -12.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.80% | -29.75% | -33.95% | -27.71% | -12.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.80% | -29.75% | -33.95% | -27.71% | -12.69% |
| EBIT | -23.19% | -32.83% | -30.77% | -35.11% | -20.82% |
| EBITDA | -23.17% | -32.88% | -30.87% | -35.26% | -20.93% |
| EPS Basic | 4.00% | 0.42% | -2.29% | 5.80% | 14.48% |
| Normalized Basic EPS | 7.92% | -1.54% | 1.02% | 4.61% | 13.60% |
| EPS Diluted | 4.00% | 0.42% | -2.29% | 5.80% | 14.48% |
| Normalized Diluted EPS | 7.92% | -1.54% | 1.02% | 4.61% | 13.60% |
| Average Basic Shares Outstanding | 38.92% | 35.05% | 29.90% | 34.69% | 31.20% |
| Average Diluted Shares Outstanding | 38.92% | 35.05% | 29.90% | 34.69% | 31.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |